# OnCo record nct05141149 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05141149/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05141149", "NCT05141149" ;
  schema:name "First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer"@en ;
  schema:description "A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Prestige Biopharma Limited, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05141149/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05141149> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-06-05" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/pbp1510/> ;
  onco:companies <https://onco.cc/companies/prestige-biopharma/> .